|
Exact Sciences Corporation (NASDAQ: EXAS) |
|
Exact Sciences Corporation
EXAS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Exact Sciences growth rates, revenue grew
by 9.76 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 542
Medical Laboratories industry recorded
growth of revenues by 2.95 %
Exact Sciences net loss decreased from $-110 millions, to $-101 millions in first quarter of 2025,
• More on EXAS's Growth
|
|
Exact Sciences realized a net loss in trailing twelve months.
Exact Sciences realized cash reduction of $ -0.02 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 3.63.
Medical Laboratories industry's Price to Sales ratio is at 2.16.
• More on EXAS's Valuation
|
|
|
|
|
Exact Sciences realized net loss in trailing twelve months.
Exact Sciences realized cash outflow of $ -0.02per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 3.63.
Medical Laboratories industry's Price to Sales ratio is at 2.16.
Exact Sciences Price to Book Ratio is at 4.28 lower than Industry Avg. of 147.2. and higher than S&P 500 Avg. of 0.01
• More on EXAS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com